NGL Fine Chem Ltd

- The company has a sanctioned long-term debt limit of INR 95 crores for its new plant project. - So far, about INR 45-46 crores has been utilized out of the INR 134 crores already spent on capex. - Worst-case scenario: debt utilization may peak at INR 95 crores; best-case scenario around INR 75 crores. - Current working capital is around INR 45 crores, expected to increase to about INR 60 crores. - No mention of any planned equity fundraising in the discussion. - Debt fundraising appears focused on managing capex and incremental working capital for expansion by FY '27-'28.

- Ongoing capital projects are on track for completion by Q4 FY '26, with commissioning scheduled for Q1 FY '27. - The new plant's first clean room under Phase 1 is already used for manufacturing validation batches. - The new plant is mainly for serving the U.S. and EU markets, plus higher-value areas like Latin America. - Some incremental operating expenses (INR1.2 to 1.5 crores per month) will arise post commissioning. - Capitalization includes interest and manpower costs directly involved in setting up the new plant; other related expenses are charged to P&L. - Peak long-term debt sanctioned for the project is INR95 crores, with expected actual utilization between INR75 to 95 crores. - The capital investment will nearly triple net block from INR64 crores (FY21) to around INR230 crores. - Expected EBITDA breakeven from the new plant by FY '28.

- Demand is currently strong and showing broad-based recovery across regions, especially in India and Asia Pacific. - Sales growth in the first half was about 22%, largely driven by volume growth, with export sales up 3-4% due to exchange rates and volume. - New plant commissioning in FY '27 aims to cater primarily to the U.S., EU, and higher-value markets like Latin America, expected to boost sales from regulated markets. - European sales are expected to reach around INR30 crores in the current fiscal year, with further ramp-up anticipated in FY '27, though exact forecasts are pending customer budgets. - U.S. FDA approvals expected starting the second half of FY '27 should enable significant sales scale-up in the U.S. market. - Continued outsourcing (15-20%) will support volume growth during capacity constraints, particularly in lower-margin markets. - Overall, sustained demand recovery and entry into regulated markets are expected to drive faster sales growth and improved profitability.

- The company expects sustained demand growth to continue over the next few quarters, indicating a positive outlook for revenue growth. - New plant commissioning is scheduled for Q1 FY '27, primarily to serve U.S., EU, and higher-value markets; this should enable volume growth and improve margins. - EBITDA breakeven for the new plant is expected in FY '28, not FY '27, indicating initial upfront costs before profitability. - Gross margins in developed markets (U.S. and Europe) are expected to be higher (~55%-60%) compared to current margins, implying improved profitability. - Operating expenses related to the new plant are anticipated to increase by INR1.2-1.5 crores per month but will support higher-margin sales. - Incremental depreciation from the new plant is estimated between INR6-8 crores annually. - Regulatory filings and approvals, especially U.S. FDA registration expected around late FY '27, are milestones that will drive future sales and earnings growth. - Overall, the capital investments position the company for faster sales growth and improved profitability beyond FY '27.

The transcript does not explicitly mention current or expected orderbook or pending orders in quantitative terms. However, some relevant points related to demand and order outlook are: - There is a strong improvement in demand across markets, including India and Asia, indicating a broad-based recovery. - The company experienced about 15%-20% outsourcing due to capacity constraints amid rising demand. - New plant commissioning in Q1 FY '27 is expected to enhance capacity specifically for the U.S., EU, and higher-value markets. - Regulatory approvals (e.g., first U.S. filing in September 2025) are expected to drive future sales growth. - Sales from European customers catering only to EU markets are expected to be around INR 30 crores in the current year. - The company is cautiously optimistic about sustained demand growth over the next few quarters. Overall, while exact orderbook numbers are not disclosed, the company reports strong demand and ongoing capacity enhancement to meet customer requirements.